Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
tofacitinib tyrosine-protein kinase jak1 small molecule NA drugbank , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.47 approved,investigational inhibitor
tofacitinib tyrosine-protein kinase jak1 small molecule NA drugbank , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]
Disease[MeSHID:D004194]		 0.47 approved,investigational inhibitor
tofacitinib tyrosine-protein kinase jak2 small molecule NA drugbank , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]
Disease[MeSHID:D004194]		 0.39 approved,investigational antagonist,inhibitor
tofacitinib tyrosine-protein kinase jak2 small molecule NA drugbank , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.39 approved,investigational antagonist,inhibitor
tofacitinib janus kinase 3 NA Successful target TTD , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]
Disease[MeSHID:D004194]		 1.77 approved inhibitor
tofacitinib tyrosine-protein kinase jak3 small molecule NA drugbank , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]
Disease[MeSHID:D004194]		 1.77 approved,investigational inhibitor
tofacitinib janus kinase 3 NA Successful target TTD , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]
Disease[MeSHID:D004194]		 1.77 approved unknown
tofacitinib tyrosine-protein kinase jak3 small molecule NA drugbank , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 1.77 approved,investigational inhibitor
tofacitinib janus kinase 3 NA Successful target TTD , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 1.77 approved unknown
tofacitinib janus kinase 3 NA Successful target TTD , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 1.77 approved inhibitor
tofacitinib non-receptor tyrosine-protein kinase tyk2 small molecule NA drugbank , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]
Disease[MeSHID:D004194]		 0.91 approved,investigational unknown
tofacitinib non-receptor tyrosine-protein kinase tyk2 small molecule NA drugbank , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.91 approved,investigational inhibitor
tofacitinib non-receptor tyrosine-protein kinase tyk2 small molecule NA drugbank , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.91 approved,investigational unknown
tofacitinib non-receptor tyrosine-protein kinase tyk2 small molecule NA drugbank , DGIDB Communicable Diseases[MeSHID:D003141]
Ankylosing spondylitis[MeSHID:D013167]
Graft Rejection[MeSHID:D006084]
Rheumatoid Arthritis[MeSHID:D001172]
Pneumonia[MeSHID:D011014]
Ulcerative Colitis[MeSHID:D003093]
Herpes zoster disease[MeSHID:D006562]
Kidney[MeSHID:D007668]
Urinary tract infection[MeSHID:D014552]
Infection[MeSHID:D007239]
Psoriasis[MeSHID:D011565]
Recurrence (disease attribute)[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]
Disease[MeSHID:D004194]		 0.91 approved,investigational inhibitor
click here to return to the previous page